Work

530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1052

Authors: F. Janku, Z. Wei, M.A. Davies, E.P. Mitchell, J.J. Wright, L.A. Doyle, R.J. Gray, V. Wang, L.M. McShane, L.V. Rubinstein, D.R. Patton, P.M. Williams, S.R. Hamilton, B. Conley, C.L. Arteaga, L.N. Harris, P.J. O'Dwyer, A.P. Chen, K.T. Flaherty

Institutions: The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Thomas Jefferson University Hospital, National Cancer Institute, National Institutes of Health, Frederick National Laboratory for Cancer Research, City Of Hope National Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Pennsylvania, Massachusetts General Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204003824

FWCI: 0.067

Cites:

Cited by: 1

Related to: 10